In early trade on January 10, Lupin’s share price experienced a 1% upswing following the company’s introduction of Bromfenac Ophthalmic Solution, 0.07%, subsequent to obtaining approval from the United States Food and Drug Administration (USFDA).
As of 09:21 hrs, Lupin was trading at Rs 1,408.60, reflecting an increase of Rs 12.55, or 0.90%, on the BSE.
Lupin holds the exclusive first-to-file status for this product, entitling the company to a 180-day exclusivity period.
The Bromfenac Ophthalmic Solution, 0.07%, serves as the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, originally developed by Bausch & Lomb Inc. It is prescribed for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery.
